Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • EC

    - PMLiVE

    J&J receives positive NICE recommendation for multiple myeloma treatment

    The treatment is approved for use within the NHS in England and Wales

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

    More than 180,000 people worldwide are diagnosed with the disease every year

    - PMLiVE

    GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

    The deal includes a PDE3/4 inhibitor in clinical development for COPD

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

    More than 50,000 cases of the blood cancer are diagnosed in Europe each year

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

    ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

    regeneron headquarters

    Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma

    More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year

    - PMLiVE

    Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication

    Around 46,000 cases of the disease are expected to be diagnosed in Europe this year

    - PMLiVE

    J&J’s Darzalex recommended by CHMP to treat smouldering multiple myeloma

    If approved, Darzalex would be the first therapy approved in the EU for SMM

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links